Literature DB >> 23671329

Suppression of Ser/Thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death.

Benjamin Theobald1, Kathy Bonness, Alla Musiyenko, Joel F Andrews, Gudrun Urban, Xizhong Huang, Nicholas M Dean, Richard E Honkanen.   

Abstract

UNLABELLED: Fostriecin is a natural product purified from Sterptomyces extracts with antitumor activity sufficient to warrant human clinical trials. Unfortunately, difficulties associated with supply and stable drug formulation stalled further development. At a molecular level, fostriecin is known to act as a catalytic inhibitor of four PPP-family phosphatases, and reports describing the design of molecules in this class suggest derivatives targeting enzymes within the fostriecin-sensitive subfamily can be successful. However, it is not clear if the tumor-selective cytotoxicity of fostriecin results from the inhibition of a specific phosphatase, multiple phosphatases, or a limited subset of fostriecin sensitive phosphatases. How the inhibition of sensitive phosphatases contributes to tumor-selective cytotoxicity is also not clear. Here, high-content time-lapse imaging of live cells revealed novel insight into the cellular actions of fostriecin, showing that fostriecin-induced apoptosis is not simply induced following a sustained mitotic arrest. Rather, apoptosis occurred in an apparent second interphase produced when tetraploid cells undergo mitotic slippage. Comparison of the actions of fostriecin and antisense-oligonucleotides specifically targeting human fostriecin-sensitive phosphatases revealed that the suppression PP4C alone is sufficient to mimic many actions of fostriecin. Importantly, targeted suppression of PP4C induced apoptosis, with death occurring in tetraploid cells following mitotic slippage. This effect was not observed following the suppression of PP1C, PP2AC, or PP5C. These data clarify PP4C as a fostriecin-sensitive phosphatase and demonstrate that the suppression of PP4C triggers mitotic slippage/apoptosis. IMPLICATIONS: Future development of fostriecin class inhibitors should consider PP4C as a potentially important target. Mol Cancer Res; 11(8); 845-55. ©2013 AACR. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23671329      PMCID: PMC3748177          DOI: 10.1158/1541-7786.MCR-13-0032

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  48 in total

1.  Genomic organization of the human PP4 gene encoding a serine/threonine protein phosphatase (PP4) suggests a common ancestry with PP2A.

Authors:  X Huang; A Cheng; R E Honkanen
Journal:  Genomics       Date:  1997-09-15       Impact factor: 5.736

Review 2.  Identification and characterization of second-generation antisense oligonucleotides.

Authors:  N M Dean; R H Griffey
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1997-06

3.  Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A.

Authors:  A H Walsh; A Cheng; R E Honkanen
Journal:  FEBS Lett       Date:  1997-10-27       Impact factor: 4.124

Review 4.  Fostriecin: a review of the preclinical data.

Authors:  R S de Jong; E G de Vries; N H Mulder
Journal:  Anticancer Drugs       Date:  1997-06       Impact factor: 2.248

5.  Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells.

Authors:  T Kanda; K F Sullivan; G M Wahl
Journal:  Curr Biol       Date:  1998-03-26       Impact factor: 10.834

6.  Inhibition of type II topoisomerase by fostriecin.

Authors:  T J Boritzki; T S Wolfard; J A Besserer; R C Jackson; D W Fry
Journal:  Biochem Pharmacol       Date:  1988-11-01       Impact factor: 5.858

7.  Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the reduced folate carrier system.

Authors:  D W Fry; J A Besserer; T J Boritzki
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

8.  Changes in nuclear chromatin related to apoptosis or necrosis induced by the DNA topoisomerase II inhibitor fostriecin in MOLT-4 and HL-60 cells are revealed by altered DNA sensitivity to denaturation.

Authors:  M A Hotz; F Traganos; Z Darzynkiewicz
Journal:  Exp Cell Res       Date:  1992-07       Impact factor: 3.905

9.  Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A.

Authors:  M Roberge; C Tudan; S M Hung; K W Harder; F R Jirik; H Anderson
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

10.  Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay.

Authors:  L Pillon; M J Moore; J J Thiessen
Journal:  Ther Drug Monit       Date:  1994-04       Impact factor: 3.681

View more
  3 in total

1.  Protein phosphatase 4 catalytic subunit is overexpressed in glioma and promotes glioma cell proliferation and invasion.

Authors:  Mengyou Li; Xin Li; Shiming Xu; Pengfei Xue; QingZhe Li; Qingyang Lu; Qingbin Jia; Lianqun Zhang; Xueyuan Li; Xingang Li
Journal:  Tumour Biol       Date:  2016-04-09

2.  High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.

Authors:  Xinxiang Li; Lei Liang; Liyong Huang; Xiaoji Ma; Dawei Li; Sanjun Cai
Journal:  Mol Cancer       Date:  2015-04-28       Impact factor: 27.401

Review 3.  Coordination of Protein Kinase and Phosphoprotein Phosphatase Activities in Mitosis.

Authors:  Isha Nasa; Arminja N Kettenbach
Journal:  Front Cell Dev Biol       Date:  2018-03-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.